

Drug Coverage Policy

Effective Date......08/01/2025
Coverage Policy Number.....IP0011
Policy Title...Brands with Bioequivalent
Generics

Brands with Bioequivalent Generics

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide quidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment quidelines. In certain markets, delegated vendor quidelines may be used to support medical necessity and other coverage determinations.

OVERVIEW

The FDA Office of Generic Drugs follows a rigorous review process to make sure that, compared to the brand-name (or innovator) medications, the proposed generic medications:

- Contain the same active/key ingredient;
- Have the same strength;
- Use the same dosage form (for instance, a tablet, capsule, or liquid); and

Page 1 of 11

Coverage Policy Number: IP0011

• Use the same route of administration (for instance, oral, topical, or injectable).

FDA's review process ensures that generic medications perform the same way in the human body and have the same intended use as the name brand medication. Health care professionals and consumers can be assured that FDA-approved generic drug products have met the same rigid standards as the innovator drug. All generic drugs approved by FDA have the same high quality, strength, purity, and stability as brand-name drugs. In addition, FDA inspects facilities to make certain the generic manufacturing, packaging, and testing sites pass the same quality standards as those of brand-name drugs.¹

A multi-sourced brand drug is a brand-name drug that is marketed or sold by two or more manufacturers or labelers, is no longer protected under patent exclusivity, and has a therapeutically equivalent generic available.

Coverage Policy

This Coverage Policy supports medical necessity review for brands with bioequivalent generic drugs available, not addressed in any other policy.

Brands with bioequivalent generic products listed in the table below are considered medically necessary when the following criteria are met:

The patient has tried the bioequivalent generic product AND cannot take due to a formulation difference in the inactive ingredient(s) [for example, difference in dyes, fillers, preservatives] between the brand and the bioequivalent generic product which, per the prescriber, would result in a significant allergy or serious adverse reaction.

Any other exception is considered not medically necessary.

All products are approved for a duration of 12 months unless otherwise noted.

Non-Covered Brand	Bioequivalent Generic
Abilify	aripiprazole
Accupril	quinapril tablet
Accuretic	quinapril/hydrochlorothiazide
Aciphex tablet	rabeprazole sodium tablets
Actos	pioglitazone
Acular 0.5% solution	ketorolac 0.5% solution
Acular LS 0.4% solution	ketorolac 0.4% solution
Aczone (5% gel and 7.5% gel pump)	dapsone topical gel
Aldactone	spironolactone
Alinia tablets	nitazoxanide tablets
Alphagan P 0.15% ophthalmic solution	brimonidine tartrate ophthalmic solution
Altace	ramipril capsule
Amitiza	lubiprostone
Anafranil	clomipramine capsules

Page 2 of 11

Coverage Policy Number: IP0011

Non-Covered Brand	Bioequivalent Generic	
Analpram-HC	pramoxine and hydrocortisone cream	
Ancobon	flucytosine capsules	
Anusol-HC 2.5% cream	hydrocortisone acetate 2.5% cream	
	hydrocortisone acetate, Anucort-HC (hydrocortisone),	
Anusol-HC 25 mg suppository	Hemmorex-HC (hydrocortisone) 25 mg suppository	
Atacand	candesartan cilexetil tablets	
Atacand HCT	candesartan/hydrochlorothiazide tablets	
Ativan	lorazepam tablets	
Atralin	tretinoin gel (0.05%)	
Augmentin tablet	amoxicillin/clavulanate potassium tablet	
Augmentin XR tablet	amoxicillin/clavulanate potassium extended-release tablet	
Augmentin suspension	amoxicillin/clavulanate potassium suspension	
Augmentin ES suspension	amoxicillin/clavulanate potassium suspension	
Avalide	irbesartan/hydrochlorothiazide tablets	
Avapro	irbesartan tablets	
-		
Avidant	dutasteride	
Azilect	rasagiline tablets	
Azopt 1% suspension	brinzolamide 1% suspension	
Azor	amlodipine besylate/olmesartan medoxomil tablets	
Azulfidine	sulfasalazine	
Baciguent ophthalmic ointment	bacitracin ophthalmic ointment	
Baraclude	entecavir	
Benicar	olmesartan medoxomil tablets	
Benicar HCT	olmesartan/hydrochlorothiazide tablets	
Bepreve 1.5% solution	bepotastine 1.5% solution	
Betapace	sotalol	
Betapace AF	sotalol	
BiDil	isosorbide dinitrate and hydralazine tablets	
	brompheniramine, dextromethorphan and	
Bromfed DM	pseudoephedrine syrup	
BromSite	bromfenac 0.075% ophthalmic solution	
Brovana 15 mcg/2 mL	•	
solution	arformoterol 15 mcg/2 mL solution	
Bystolic	nebivolol	
Canasa	mesalamine rectal suppository	
Carafate suspension	sucralfate oral suspension	
Carafate tablet	sucralfate tablet	
Carbatol	carbamazepine ER	
Cardizem	diltiazem hcl tablet	
Cardizem CD	diltiazem extended-release capsules	
Cardizem LA	diltiazem extended-release tablets	
Carnitor	levocarnitine	
Carnitor SF	levocarnitine sugar free oral solution	
Cellcept 200mg/ml oral	myconhanolate mofetil oral suspension	
suspension	mycophenolate mofetil oral suspension	
Cellcept 250mg capsule	mycophenolate mofetil capsules	
Cellcept 500mg tablet	mycophenolate mofetil tablets	

Page 3 of 11 Coverage Policy Number: IP0011

Non-Covered Brand	Bioequivalent Generic	
Celebrex	celecoxib capsules	
Celexa	citalopram	
Celontin	methsuximide	
Climara	estradiol patch	
Chantix	varenicline	
Ciloxan 0.3% solution	ciprofloxacin 0.3% solution	
Ciprodex	ciprofloxacin / dexamethasone otic suspension	
Cleocin vaginal cream	clindamycin vaginal cream	
Clobex 0.05% Shampoo	clobetasol 0.05% shampoo	
Clobex 0.05% Spray	clobetasol 0.05% spray	
Clozaril	clozapine	
Colcrys	colchicine tablet	
Combigan ophthalmic solution	brimonidine tartrate/timolol maleate ophthalmic solution	
Coreg	carvedilol tablet	
Coreg CR	carvedilol extended-release capsule	
Corgard	nadolol	
Cortef	hydrocortisone tablet	
Cosopt solution	dorzolamide and timolol solution	
Cosopt PF solution	dorzolamide and timolol preservative free solution	
Coumadin	warfarin	
Cozaar	losartan tablet	
Cymbalta	duloxetine delayed-release capsules	
Cytomel	liothyronine	
DDAVP injection	desmopressin acetate injection	
DDAVP tablet	desmopressin acetate tablet	
Delestrogen intramuscular		
injection	estradiol valerate intramuscular injection	
Depakote	divalproex sodium	
Depakote ER	divalproex sodium ER	
Depakote sprinkle	divalproex sodium	
Desowen cream	desonide cream	
Detrol	tolterodine tablets	
Detrol LA	tolterodine ER capsules	
Dexilant	dexlansoprazole delayed-release capsules	
Diastat, Diastat Acudial	diazepam	
·	doxylamine succinate and pyridoxine hydrochloride delayed-	
Diclegis	release tablets	
Diflucan suspension	fluconazole suspension	
Diflucan tablet	fluconazole tablet	
Dilantin, Dilantin-125,		
Phenytek	phenytoin	
Diovan	valsartan tablets	
Diovan HCT	valsartan/hydrochlorothiazide tablets	
Divigel	estradiol 0.1% gel	
Durezol 0.05% emulsion	difluprednate 0.05% emulsion	
Dyrenium	triamterene	
	erythromycin ethylsuccinate 200 mg/5 mL granules for	
E.E.S. 200 mg/5 mL	suspension	
Effexor XR	venlafaxine hydrochloride extended-release capsule	
Elidel	pimecrolimus	
Lilaci	pinicalonina	

Page 4 of 11 Coverage Policy Number: IP0011

Non-Covered Brand	Bioequivalent Generic
Elixophyllin	theophylline 80 mg/15 mL solution
Emend capsules and Emend	
Trifold Pack	aprepitant oral capsules
	enalapril maleate powder for oral solution, enalapril maleate
Epaned	oral solution
EryPed 400	erythromycin 400 mg/5 mL suspension
Estrace tablets	estradiol tablets
Estrace cream	estradiol cream
Estrogel	estradiol gel 0.06%
Exforge	amlodipine and valsartan
Exforge HCT	amlodipine, valsartan and hydrochlorothiazide
Evoxac	cevimeline hydrochloride capsules
Felbatol	felbamate
Femara	letrozole tablets
Flomax	tamsulosin hydrochloride capsules
FML	fluorometholone
FML Liquifilm 0.1%	
suspension	fluorometholone 0.1% suspension
Fosrenol Chewable Tablet	lanthanum carbonate chewable tablet
Furadantin 25 mg/5 mL oral	
suspension	nitrofurantoin 25 mg/5 mL oral suspension
Gabitril	tiagabine hydrochloride
Gastrocrom	cromolyn sodium 100mg/5mL solution
Geodon	ziprasidone
Halog 0.1% solution	halcinonide 0.1% solution
Hyzaar	losartan/hydrochlorothiazide tablets
Imuran	azathioprine tablets
Inderal LA	propranolol extended-release capsule
Inspra	eplerenone
Intuniv	guanfacine ER
Istalol 0.5% solution	timolol maleate 0.5% solution
Isordil Titradose 5mg	isosorbide dinitrate 5mg tablet
Jalyn	dutasteride / tamsulosin
Kapvay	clonidine ER tablet
Keppra	levetiracetam
Keppra XR	levetiracetam extended release
Klonopin	clonazepam
Lamictal	lamotrigine
Lamictal ODT	lamotrigine ODT
Lamictal XR	lamotrigine extended release
Lanoxin	digoxin
Lasix	furosemide
Latuda	lurasidone
Levbid	hyoscyamine sulfate extended-release tablets
Levsin SL	hyoscyamine sulfate sublingual tablets
Lexapro	escitalopram tablets
Lialda	mesalamine delayed-release tablet
Librax	chlordiazepoxide hydrochloride; clidinium bromide
Lidoderm 5% topical patch	lidocaine 5% topical patch
Lithobid	lithium
5514	1

Page 5 of 11 Coverage Policy Number: IP0011

Non-Covered Brand	Bioequivalent Generic	
Lomotil	diphenoxylate/atropine	
Lopressor	metoprolol tartrate	
Lotemax 0.5% ophthalmic gel	loteprednol 0.5% ophthalmic gel	
Lotemax 0.5% ophthalmic		
suspension	loteprednol 0.5% ophthalmic suspension	
Lotensin	benazepril tablet	
Lotensin HCT	benazepril/hydrochlorothiazide	
Lotrel	amlodipine/benazepril capsule	
Lovaza	omega-3-acid ethyl esters capsule	
Lunesta	eszopiclone	
Lyrica	pregabalin	
Malarone	atovaquone / proguanil	
Maxitrol ointment	neomycin, polymyxin B, and dexamethasone ointment	
Maxitrol suspension	neomycin, polymyxin B, and dexamethasone suspension	
Mepron	atovaquone	
Mestinon	pyridostigmine	
Metrogel vaginal	Metronidazole vaginal	
Micardis	telmisartan tablets	
Micardis HCT	telmisartan/hydrochlorothiazide tablets	
Minivelle	estradiol transdermal patch	
Mycobutin	rifabutin	
Myfortic	mycophenolic acid	
Myrbetriq tablets	mirabegron extended-release tablets	
Mysoline	primidone	
Nardil	phenelzine	
Natroba	spinosad topical suspension	
Neoral capsule	cyclosporine capsule	
Neoral oral solution	cyclosporine oral solution	
Neurontin	gabapentin	
Nexium DR capsules	esomeprazole delayed-release capsules	
Nexium DR packet	esomeprazole delayed-release granules for oral suspension	
Norpace	disopyramide phosphate	
Norpramin	desipramine	
Norvasc	amlodipine tablets	
Noxafil 40mg/ml (200mg/5ml) oral suspension	posaconazole 40mg/ml (200mg/5ml) oral suspension	
Noxafil tablet	posaconazole tablet	
Ocuflox 0.3% solution	ofloxacin 0.3% solution	
Onfi	clobazam	
Pacerone	amiodarone	
Pamelor	nortriptyline capsules	
Parnate	tranylcypromine tablets	
Patanol 0.1% solution	olopatadine 0.1% solution	
Paxil	paroxetine hydrochloride	
Paxil CR	paroxetine hydrochloride extended-release tablet	
Pentasa 500 mg	mesalamine 500 mg extended-release capsule	
Pepcid	famotidine	
Perforomist 20 mcg/2 mL		
solution	formoterol 20 mcg/2 mL solution	

Page 6 of 11 Coverage Policy Number: IP0011

Non-Covered Brand	Bioequivalent Generic	
Plaquenil	hydroxychloroquine sulfate tablet	
Plavix	clopidogrel bisulfaste tablets	
Polytrim solution	trimethoprim and polymyxin B solution	
Pred Forte 1% suspension	prednisolone 1% suspension	
Prenatabs FA	prenatal vitamin, iron 29 mg/folic acid 1 mg	
Prevacid SoluTab	lansoprazole delayed release orally disintegrating tablets	
Prevident 5000 Plus	sodium fluoride 1.1% cream/paste	
Prezista 600mg and 800mg	darunavir oral tablets	
tablets	Desvenlafaxine succinate extended-release tablet	
Pristiq		
Procardia XL	nifedipine extended-release	
Proglycem suspension	diazoxide oral suspension	
Prograf capsule	tacrolimus	
Prometrium	progesterone	
Protopic	tacrolimus ointment	
Provera	medroxyprogesterone acetate tablet	
Prozac	fluoxetine	
Pulmicort respules	budesonide respules	
Pyridium	phenazopyridine tablets	
Qualaquin	quinine sulfate	
Qudexy XR	topiramate	
Ranexa	ranolazine	
Rapamune	sirolimus	
Remeron	mirtazapine	
Renagel tablet	sevelamer hydrochloride tablet	
Renvela tablet	sevelamer carbonate tablet	
Renvela powder packet	sevelamer carbonate powder packet	
Rilutek	riluzole	
Risperdal	risperidone	
Risperdal Consta	risperidone intramuscular injection	
Rowasa	mesalamine rectal suspension	
Rozerem	ramelteon	
Rythmol SR	propafenone HCL ER	
Salex 6% cream kit	salicylic acid 6% cream	
Salex 6% lotion kit	salicylic acid 6% lotion	
Salex 6% shampoo	salicylic acid 6% shampoo	
Samsca	tolvaptan	
Sandimmune	cyclosporine	
Sensipar	cinacalcet	
Singulair	montelukast sodium tablets, chewable tablets, granules	
Silenor	doxepin tablet	
Soma	carisoprodol	
Spiriva HandiHaler	tiotropium bromide inhalation powder	
Sporanox capsule	itraconazole capsule	
Sporanox solution	itraconazole solution	
Strattera	atomoxetine	
Sulfatrim	sulfamethoxazole/trimethoprim (co-trimoxazole; TMP-SMZ)	
Symbyax	olanzapine and fluoxetine capsule	
Synthroid	levothyroxine tablets	
27	in the factor of	

Page 7 of 11 Coverage Policy Number: IP0011

Non-Covered Brand	Bioequivalent Generic	
Taclonex suspension	calcipotriene/betamethasone dipropionate 0.005%-0.064%	
	suspension	
Tamiflu	oseltamivir phosphate	
Tasmar	tolcapone	
Tekturna	aliskiren	
Tegretol	carbamazepine	
Tegretol XR	carbamazepine extended release	
Tenoretic	atenolol and chlorthalidone	
Tenormin	atenolol	
Tikosyn	dofetilide	
Timoptic 0.25% solution	timolol maleate 0.25% solution	
Timoptic 0.5% solution	timolol maleate 0.5% solution	
Timoptic 0.5% Ocudose solution	timolol maleate 0.5% solution	
Timoptic XE 0.25% gel solution	timolol maleate 0.25% gel forming solution	
Timoptic XE 0.5% gel solution	timolol maleate 0.5% gel forming solution	
Tobradex suspension	tobramycin and dexamethasone suspension	
Tobrex 0.3% solution	tobramycin 0.3% solution	
Topamax	topiramate	
Toprol XL	metoprolol succinate extended-release tablet	
Toviaz	fesoterodine fumarate	
Tranxene T-tab	Clorazepate dipotassium tablet	
Tribenzor	olmesartan/amlodipine/hydrochlorothiazide tablets	
Trileptal	oxcarbazepine	
Trusopt 2% solution	dorzolamide2% solution	
Uloric	febuxostat	
Unithroid	levothyroxine tablets	
Uroxatral	alfuzosin tablets	
Vagifem	estradiol vaginal tablet	
Valcyte solution	valganciclovir hydrochloride solution	
Valcyte solution Valcyte tablet	valganciclovir hydrochloride solution	
Valium	diazepam tablets	
Vancocin	vancomycin hydrochloride	
Vanos 0.1% cream	fluocinonide 0.1% cream	
Vasetes	enalapril/hydrochlorothiazide tablet	
Vasion	enalapril tablet	
Vesicare	solifenacin tablets	
Vigamox 0.5% solution	moxifloxacin 0.5% solution	
Viibryd	vilazodone	
Vimpat	lacosamide	
Vitatrue	prenatal vitamin, iron 30 mg/folic acid 1.4 mg/DHA 300 mg	
Vivelle-DOT	estradiol transdermal patch	
Vytorin	ezetimibe/simvastatin tablets	
Wellbutrin SR	bupropion hydrochloride extended-release tablet	
Wellbutrin XL	bupropion extended release	
Welchol packet	colesevelam packet	
Welchol tablet	colesevelam tablet	
Xanax	alprazolam tablets	
Xanax XR	alprazolam entended-release tablets	

Page 8 of 11 Coverage Policy Number: IP0011

Non-Covered Brand	Bioequivalent Generic
Zarontin	ethosuximide
Zestoretic	lisinopril/hydrochlorothiazide tablet
Zestril	lisinopril tablet
Zetia	ezetimibe tablets
Ziac	bisoprolol and hydrochlorothiazide
Zoloft	sertraline
Zonegran	zonisamide
Zovirax capsule	acyclovir capsule
Zovirax suspension	acyclovir suspension
Zovirax tablet	acyclovir tablet
Zyloprim	allopurinol tablet
Zymaxid 0.5% solution	gatifloxacin 0.5% solution
Zyprexa	olanzapine
Zyprexa Zydis	olanzapine

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

Receipt of sample product does not satisfy any criteria requirements for coverage.

References

1. U.S Food and Drug Administration. Generic Drugs Overview & Basics: http://www.fda.gov/drugs/generic-drugs/overview-basics. Accessed on 4/10/2025.

Revision Details

Type of Revision	Summary of Changes	Date
Annual Revision	Removed diagnosis requirement from the following products: Felbatol, Keppra, Keppra XR, Lamictal, Lamictal ODT, Lamictal XR, Qudexy XR, Topamax, Trileptal, Vimpat, and Zonegran and to now support medical necessity review for both Employer Plans and Individual and Family Plans. Added to the policy to support medical necessity review for Individual and Family Plans: Atralin, Differin 0.1% cream, Differin 0.3% gel pump, Retin-A cream, Retin-A gel, Retin-A Micro gel, Retin-A Micro Pump gel	7/15/2024
Selected Revision	Added Moviprep, Mepron (Mepron effective 9/1/2024)	8/15/2024
Selected Revision	Added Myrbetriq to support medical necessity review for Employer plans.	9/1/2024

Page 9 of 11

Coverage Policy Number: IP0011

	Added Ancobon to support medical necessity review for Individual and Family Plans.	
Selected Revision	Added to the policy to support medical necessity review for Employer Plans: Accupril, Accuretic, Altace (applies to Value/Advantage/Total Savings and Individual and Family Plans), Anafranil, Ativan, Cardizem CD, Clobex 0.05% shampoo, Clobex 0.05% Spray, Cymbalta, Detrol, Detrol LA, Elixophyllin, EryPed 400, Halog 0.1% cream, Lexapro, Lotensin, Lotensin HCT, Lotrel, Pamelor, Parnate, Toviaz, Vanos 0.1% cream, Vaseretic, Vasotec, Vesicare, Zestoretic, Zestril.	10/15/2024
Selected Revision	The following were added to the policy to support medical necessity review: Effective 11/1/2024 Added for Employer Plans: Cytomel (Individual and Family plans already utilize this policy), Synthroid, Unithroid Effective 1/1/2025 Added for Employer Plans and Individual and Family Plans: Aciphex tablet, Altace, Atacand, Atacand HCT, Avalide, Avapro, AZOR, Benicar, Benicar HCT, Carafate tablets, Cardizem LA, Cellcept 200mg/ml oral suspension, Cellcept 250mg capsule, Cellcept 500mg tablet, Cozaar, Diovan, Diovan HCT, Emend 80mg capsule and Emend Trifold Pack, Estrace cream, Exforge, Exforge HCT, Flomax, Hyzaar, Lomotil, Micardis, Micardis HCT, Natroba, Noxafil tablet (added dosage form to clarify tablet and suspension), Provera, Rapamune, Soma, Tribenzor, Vagifem, Valium, Xanax, Xanax XR, Zestril Added for Employer Plans: Diclegis, BiDil, Carafate suspension, Epaned, Estrace tablet (Individual and Family Plans already utilize this policy), Aczone (5% gel and 7.5% gel pump) Added for Individual and Family Plans: Celontin, Prezista 600mg and 800mg tablets, Noxafil 40mg/ml oral suspension (Employer plans already utilize this policy for tablet and suspension), Welchol (Employer plans already utilize this policy)	11/01/2024
Solocted Davision		01/01/2025
Selected Revision Selected Revision	Removed Moviprep and Suprep Added Pepcid to support medical necessity review for Employer Plans and Individual and Family Plans.	01/01/2025 04/01/2025

Page 10 of 11 Coverage Policy Number: IP0011

	Removed Marinol; the criteria has been relocated to Dronabinol Products – (IP0719).	
Selected Revision	Updated Halog 0.1% cream to now read Halog 0.1% solution.	05/01/2025
Annual Revision	Added for Employer Plans: Alinia tablets, Azilect, BromSite, Celebrex, Desowen cream, Estrogel, Evoxac, Femara, Gastrocrom, Imuran, Levbid, Levsin SL, Norvasc, Plavix, Prevident 5000 Plus, Pulmicort respules, Pyridium, Spiriva Handihaler, Singulair, Taclonex suspension, Uroxatral, Vytorin, Zetia.	07/01/2025
	Added for Individual and Family Plans: Azilect, Celebrex, Desowen cream, Evoxac, Femara, Gastrocrom, Imuran, Levbid, Levsin SL, Norvasc, Plavix, Pulmicort respules, Pyridium, Singulair, Uroxatral, Vytorin, Zetia.	
	Removed for Employer Plans: Differin 0.1% cream, Differin 0.3% gel pump, Retin-A cream (0.025%, 0.05%, 0.1%), Retin-A gel (0.025%, 0.01%), Retin-A Micro gel (0.04% & 0.1%), Retin-A Micro Pump gel (0.04%, 0.08%, 0.1%).	
Selected Revision	Added for Employer Plans: Climara, Dexilant, Divigel, Nexium DR capsules, Nexium DR packets, Prevacid SoluTabs	8/1/2025
	Added for Individual and Family Plans: Climara, Dexilant, Nexium DR capsules, Nexium DR packets	
	Added extended release to generic lamotrigine for Lamictal XR	
	Updated Azopt 1% from solution to suspension	

The policy effective date is in force until updated or retired.

[&]quot;Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.